Volume 74, Issue 6, Pages (December 2018)

Slides:

Advertisements

Similar presentations

Volume 62, Issue 4, Pages (October 2012)

Advertisements

Volume 56, Issue 5, Pages (November 2009)

Volume 50, Issue 3, Pages (September 2006)

Volume 68, Issue 2, Pages (August 2015)

Volume 68, Issue 6, Pages (December 2015)

Volume 52, Issue 1, Pages (July 2007)

Volume 51, Issue 2, Pages (February 2007)

Volume 70, Issue 6, Pages (December 2016)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 59, Issue 1, Pages (January 2011)

Testosterone Therapy in Men With Prostate Cancer

Volume 72, Issue 6, Pages (December 2017)

Volume 53, Issue 4, Pages (April 2008)

Volume 71, Issue 1, Pages (January 2017)

Volume 61, Issue 5, Pages (May 2012)

Volume 74, Issue 2, Pages (August 2018)

Volume 73, Issue 6, Pages (June 2018)

Volume 66, Issue 3, Pages (September 2014)

Volume 52, Issue 4, Pages (October 2007)

Volume 61, Issue 3, Pages (March 2012)

Volume 63, Issue 4, Pages (April 2013)

Volume 68, Issue 1, Pages (July 2015)

Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer Sam Ladjevardi, Gabriel Sandblom,

Volume 54, Issue 4, Pages (October 2008)

Volume 60, Issue 5, Pages (November 2011)

Towards Early and More Specific Diagnosis of Prostate Cancer

Prostate Cancer Detection: A View of the Future

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 54, Issue 5, Pages (November 2008)

Volume 68, Issue 3, Pages (September 2015)

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Volume 69, Issue 3, Pages (March 2016)

Volume 66, Issue 6, Pages (December 2014)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 53, Issue 4, Pages (April 2008)

Volume 72, Issue 1, Pages (July 2017)

Volume 54, Issue 3, Pages (September 2008)

Volume 66, Issue 2, Pages (August 2014)

Volume 74, Issue 2, Pages (August 2018)

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 65, Issue 6, Pages (June 2014)

Volume 74, Issue 2, Pages (August 2018)

Volume 68, Issue 4, Pages (October 2015)

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Volume 58, Issue 1, Pages (July 2010)

Volume 62, Issue 6, Pages (December 2012)

Volume 50, Issue 5, Pages (November 2006)

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

Prostate Cancer Nomograms: An Update

Volume 71, Issue 5, Pages (May 2017)

Jacques Irani European Urology Supplements

PSA Levels and the Probability of Prostate Cancer on Biopsy

Volume 59, Issue 4, Pages (April 2011)

Volume 70, Issue 1, Pages (July 2016)

Volume 71, Issue 4, Pages (April 2017)

Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg

Thomas Steuber, Matthew Frank O'Brien, Hans Lilja European Urology

Volume 74, Issue 6, Pages (December 2018)

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.

Volume 54, Issue 5, Pages (November 2008)

The Comparability of Models for Predicting the Risk of a Positive Prostate Biopsy with Prostate-Specific Antigen Alone: A Systematic Review Fritz Schröder,

Volume 52, Issue 6, Pages (December 2007)

Volume 68, Issue 2, Pages (August 2015)

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Volume 53, Issue 2, Pages (February 2008)

Volume 51, Issue 2, Pages (February 2007)

Volume 54, Issue 3, Pages (September 2008)

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Does PSA Testing Influence the Natural History of Prostate Cancer?

Assessing a Patient’s Individual Risk of Biopsy-detectable Prostate Cancer: Be Aware of Case Mix Heterogeneity and A Priori Likelihood Jan F.M. Verbeek,

Presentation transcript:

Volume 74, Issue 6, Pages 731-738 (December 2018) A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2–10ng/ml at Initial Biopsy James McKiernan, Michael J. Donovan, Eric Margolis, Alan Partin, Ballentine Carter, Gordon Brown, Phillipp Torkler, Mikkel Noerholm, Johan Skog, Neal Shore, Gerry Andriole, Ian Thompson, Peter Carroll European Urology Volume 74, Issue 6, Pages 731-738 (December 2018) DOI: 10.1016/j.eururo.2018.08.019 Copyright © 2018 The Author(s) Terms and Conditions

Fig. 1 Area under receiver operating characteristic (AUC) curves are shown to compare performances of EPI in (A) the current cohort (n=503) and (B) the previous validation cohort (n=519) with and without the SOCm, PCPT-RC, ERSPC-RC, and PSA alone. The corresponding net benefit analysis for the two cohorts is shown (C) for current validation cohort and (D) for previous validation cohort. EPI=ExoDx Prostate (IntelliScore); ERSPC-RC=European Randomized Study of Screening for Prostate Cancer risk calculator; PCPT-RC=Prostate Cancer Prevention Trial risk calculator; PSA=prostate-specific antigen; SOCm=standard of care model. European Urology 2018 74, 731-738DOI: (10.1016/j.eururo.2018.08.019) Copyright © 2018 The Author(s) Terms and Conditions

Fig. 2 Waterfall plot of the EPI scores in relation to prostate biopsy outcomes across cohort 1 (n=503). EPI scores are shown on Y-axis and the Grade Group biopsy results illustrated in blue, yellow, or red. EPI=ExoDx Prostate (IntelliScore); GG=Grade Group. European Urology 2018 74, 731-738DOI: (10.1016/j.eururo.2018.08.019) Copyright © 2018 The Author(s) Terms and Conditions